It is a promising therapeutic agent for solid organ transplantations and cancer treatments.4 In addition to the direct antiproliferative effect on tumour cells, rapamycin impedes tumour growth by blocking angiogenesis in a mouse metastatic cancer model.5 LBH589 (panobinostat), a non‐selective histone deacetylase inhibitor (pan‐HDAC inhibitor), has been shown to induce tumour shrinkage and sustain stable disease status in a phase II trial of pre‐treated lung cancer patients.6 LBH589 is the first HDAC inhibitor to be approved by the FDA to treat multiple myeloma patients.7 The gene discussed is HDAC9; the disease is metastatic malignant neoplasm.